[EN] 2,3-BENZOXAZIN DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS<br/>[FR] DERIVES DE 2,3-BENZOXAZINE UTILISES EN TANT QUE MODULATEURS NON STEROIDIENS DU RECEPTEUR GLUCOCORTICOIDE
申请人:GLAXO GROUP LTD
公开号:WO2006000398A1
公开(公告)日:2006-01-05
The present invention provides compounds of formula (I), wherein R1 represents 1-ethylpropyl, 1-methylethyl or 2-methylpropyl; or a physiologically functional derivative thereof; pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
The present invention relates to an apparatus for producing alcohols from olefins, comprising: a hydroformylation reactor wherein aldehydes are produced from olefins; a catalyst/aldehydes separator; a hydrogenation reactor wherein the aldehydes are hydrogenated to produce alcohols; and a distillation column. The hydroformylation reactor is equipped with a distributor plate, which has a broad contact surface for providing sufficient reaction area for reactants such as olefins and synthesis gas, and allows the reaction mixture to circulate and mix sufficiently, which contribute to excellent efficiency in terms of production of aldehydes. In addition, the hydrogenation reactor suppresses sub-reactions to improve the production yield of alcohols.
A process for producing purified alcohols yielding good results in the acid wash color test which comprises the condensation step of subjecting an aldehyde to aldol condensation and dehydration to obtain a corresponding condensate, the hydrogenation step of hydrogenating the condensate into a crude alcohol, and the purification step of distilling the crude alcohol to obtain a purified alcohol, characterized by feeding into the purification step a crude alcohol containing compounds having oxygenic heterocycles bearing carbon-carbon double bonds in the cycle in a concentration of as low as 200 ppm by weight or below. In particular, the aldehyde is n-butyraldehyde, the condensate is 2-ethylhexenal, and the alcohol is 2-ethylhexanol.
[EN] PROCESS FOR THE PRODUCTION OF 2-ALKYLALKANOL<br/>[FR] PROCÉDÉ DE PRODUCTION DE 2-ALKYLALCANOL
申请人:JOHNSON MATTHEY DAVY TECHNOLOGIES LTD
公开号:WO2018069714A1
公开(公告)日:2018-04-19
A process for the production of 2-alkylalkanol from an aldehyde is disclosed. The process comprises the steps of: feeding aldehyde to a reactor (42) operated under condensation and dehydration conditions such that reaction occurs and an unsaturated aldehyde is produced; recovering a stream from the reactor (42) comprising the unsaturated aldehyde and feeding said stream to a first hydrogenation reactor (45) operated under conditions such that at least some of the unsaturated aldehyde is converted to 2-alkylalkanol; recovering the stream from the first hydrogenation reactor (45) comprising the 2-alkylalkanol, one or more of unreacted acrolein, alkylalkenol and alkylalkanal and heavies; passing the stream recovered from the first hydrogenation reactor (45) to a first distillation zone (48) where at least some of the heavies are separated from the stream; recovering a stream from the first distillation zone (48) comprising the 2-alkylalkanol, one or more of unreacted acrolein, alkylalkenol and alkylalkanal, said stream having a reduced heavies content when compared to the stream fed to the first distillation zone (48), and feeding said stream to a second hydrogenation reactor (51) operated under conditions such that at least one of the unreacted acrolein, alkylalkenol and alkylalkanal are converted to 2-alkylalkanol; and recovering a stream from the second hydrogenation reactor (51) comprising an increased 2-alkylalkanol content compared to the stream fed to the second hydrogenation reactor (51).
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.